Citation only
via Europe PMC
Mitochondrial dysfunction in Alzheimer's disease: mechanisms, pathogenic interplay, and therapeutic opportunities.
Dou B, Chen J, Zhao H, Sun-Yan A, Zhu X, Xu Y.
Pharmacology & therapeutics · 2026
Genomic instability
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Human
Preclinical / animal
Abstract
Alzheimer's disease (AD) remains a major cause of dementia, yet effective disease-modifying therapies are still limited. Although amyloid-β (Aβ) and tau pathology remain core features of AD pathogenesis, they do not fully explain how these pathological alterations drive progressive cellular dysfunction. Increasing evidence suggests that mitochondria are involved at this critical interface. In AD, mitochondrial abnormalities impair energy production, compromise organelle quality control, disrupt calcium (Ca<sup>2+</sup>) homeostasis, and alter communication with the endoplasmic reticulum and glial cells. As these defects accumulate, neurons and glia become less able to maintain metabolic stability, redox balance, and synaptic function. Mitochondrial dysfunction(definition) is therefore relevant to AD not as a single isolated lesion, but as a convergent process through which metabolic failure, oxidative stress, mitochondrial DNA damage, inflammatory signaling, and defective cellular maintenance reinforce one another. This perspective also helps explain why disease progression is difficult to reverse once mitochondrial homeostasis has been broadly compromised. At the same time, this framework also points to therapeutic opportunities, as the mechanisms driving the development and progression of mitochondrial dysfunction may be amenable to intervention. However, many mitochondria-centered strategies remain preclinical or have yielded inconsistent clinical benefit. Current evidence supports mitochondrial dysfunction as both a useful mechanistic basis for understanding AD progression and a biologically meaningful, though challenging, therapeutic target.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1016/j.pharmthera.2026.109130
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
B, D., J, C., H, Z., A, S., X, Z., & Y., X. (2026). Mitochondrial dysfunction in Alzheimer's disease: mechanisms, pathogenic interplay, and therapeutic opportunities. <em>Pharmacology & therapeutics</em>. https://doi.org/10.1016/j.pharmthera.2026.109130
Vancouver
B D, J C, H Z, A S, X Z, Y. X. Mitochondrial dysfunction in Alzheimer's disease: mechanisms, pathogenic interplay, and therapeutic opportunities. Pharmacology & therapeutics. 2026. doi:10.1016/j.pharmthera.2026.109130.
BibTeX
@article{dou2026Mitoch,
title = {Mitochondrial dysfunction in Alzheimer's disease: mechanisms, pathogenic interplay, and therapeutic opportunities.},
author = {Dou B and Chen J and Zhao H and Sun-Yan A and Zhu X and Xu Y.},
journal = {Pharmacology & therapeutics},
year = {2026},
doi = {10.1016/j.pharmthera.2026.109130},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
npj Aging 2026
Open access · CC-BY
Targeting mitophagy for neuroprotection: mechanisms and therapeutic opportunities
International Journal of Molecular Sciences 2021
Open access · CC-BY
The Link between Oxidative Stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS
Frontiers in cell and developmental biology 2026
Open access · OA
Mitochondria in health and disease: cellular powerhouses, signaling centers, and drivers of dysfunction.
Nature and Science of Sleep 2025
Open access · CC-BY
Circadian Rhythm Dysfunction in Neurodegenerative Diseases: A Bidirectional Perspective and Therapeutic Potential
Antioxidants 2023
Open access · CC-BY
Effects of Redox Homeostasis and Mitochondrial Damage on Alzheimer’s Disease
Frontiers in Aging Neuroscience 2021
Open access · CC-BY